This is compared with the guidance in place at the time of the meeting, which stipulated that individuals with a GPV in BRCA1/BRCA2/PALB2 were only eligible for breast cancer surveillance at age 25–30 years if they reached a 10-year risk of 8% or greater. This evidence concerns the gene PALB2 and breast carcinoma.